PubRank

Janet S Rader

Author PubWeight™ 85.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008 4.24
2 Resource utilization for ovarian cancer patients at the end of life: how much is too much? Gynecol Oncol 2005 2.26
3 A microRNA expression signature for cervical cancer prognosis. Cancer Res 2010 2.14
4 Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply? Gynecol Oncol 2004 2.08
5 Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2009 2.05
6 Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol 2007 1.87
7 Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003 1.83
8 Use of complementary and alternative medicine among women with gynecologic cancers. Gynecol Oncol 2002 1.72
9 Cervical carcinoma in the elderly: an analysis of patterns of care and outcome. Cancer 2005 1.68
10 Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009 1.60
11 Chemoradiation in locally advanced cervical carcinoma: an analysis of cisplatin dosing and other clinical prognostic factors. Gynecol Oncol 2009 1.59
12 Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 2004 1.57
13 Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010 1.55
14 Utility of parametrectomy for early stage cervical cancer treated with radical hysterectomy. Cancer 2007 1.38
15 Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 2003 1.36
16 ATR mutation in endometrioid endometrial cancer is associated with poor clinical outcomes. J Clin Oncol 2009 1.25
17 Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer 2005 1.20
18 Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res 2007 1.17
19 Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004 1.15
20 Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys 2005 1.11
21 Pathway-specific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 2012 1.09
22 Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2002 1.08
23 Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer 2006 1.07
24 Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer. Gynecol Oncol 2006 1.05
25 Cervical tissue collection methods for RNA preservation: comparison of snap-frozen, ethanol-fixed, and RNAlater-fixation. Diagn Mol Pathol 2006 1.02
26 CD83 gene polymorphisms increase susceptibility to human invasive cervical cancer. Cancer Res 2007 1.01
27 A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 2010 1.01
28 DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006 0.99
29 Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res 2008 0.98
30 HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer. Immunogenetics 2010 0.97
31 Cervical sarcomas: an analysis of incidence and outcome. Gynecol Oncol 2005 0.96
32 Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002 0.96
33 The significance of pneumatosis intestinalis or bowel perforation in patients with gynecologic malignancies. Gynecol Oncol 2002 0.96
34 Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol 2008 0.95
35 Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007 0.94
36 Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol Oncol 2007 0.94
37 Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol 2005 0.94
38 IGSF4 promoter methylation and expression silencing in human cervical cancer. Gynecol Oncol 2005 0.94
39 Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 2004 0.94
40 Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol 2008 0.93
41 Pathway index models for construction of patient-specific risk profiles. Stat Med 2012 0.93
42 External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer. Gynecol Oncol 2007 0.91
43 Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 2002 0.90
44 Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol 2006 0.90
45 Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2002 0.90
46 The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer 2010 0.89
47 TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol Biomarkers Prev 2010 0.88
48 Qualitative Evaluation of Medical Information Processing Needs of 60 Women Choosing Ovarian Cancer Surveillance or Prophylactic Oophorectomy. J Genet Couns 2002 0.88
49 Differential display identifies overexpression of the USP36 gene, encoding a deubiquitinating enzyme, in ovarian cancer. Int J Med Sci 2008 0.88
50 Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma. Int J Radiat Oncol Biol Phys 2006 0.87
51 Synchronous ovarian metastases at the time of laparotomy for colon cancer. Gynecol Oncol 2004 0.87
52 Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 2004 0.86
53 CD83 polymorphisms and cervical cancer risk. Gynecol Oncol 2009 0.86
54 Colposcopic accuracy of obstetrics and gynecology residents. Gynecol Oncol 2006 0.85
55 "Surgical Apgar Score" predicts postoperative complications after cytoreduction for advanced ovarian cancer. Gynecol Oncol 2009 0.85
56 Cervical dysplasia in adolescents. Obstet Gynecol 2005 0.85
57 MLH3 mutation in endometrial cancer. Cancer Res 2006 0.84
58 Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 2009 0.84
59 Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013 0.84
60 A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 2004 0.83
61 Long-term assessment of bladder and bowel dysfunction after radical hysterectomy. Gynecol Oncol 2009 0.83
62 Human papillomavirus triage for young women with atypical squamous cells of undetermined significance. Obstet Gynecol 2006 0.83
63 Outcomes in 24 selected patients with stage IVB cervical cancer and excellent performance status treated with radiotherapy and chemotherapy. Radiat Med 2006 0.83
64 Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol 2003 0.82
65 Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006 0.82
66 Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data. Gynecol Oncol 2006 0.81
67 Fine mapping and evaluation of candidate genes for cervical cancer on 11q23. Genes Chromosomes Cancer 2005 0.81
68 Epithelial ovarian tumors of low malignant potential: the role of microinvasion. Obstet Gynecol 2002 0.81
69 Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer. Radiat Med 2007 0.81
70 Polymorphisms in MMP9 and SIPA1 are associated with increased risk of nodal metastases in early-stage cervical cancer. Gynecol Oncol 2009 0.80
71 CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 2006 0.79
72 Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies. Cancer 2003 0.79
73 FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys 2005 0.79
74 Liquid-based cytology for the postirradiation surveillance of women with gynecologic malignancies. Gynecol Oncol 2003 0.79
75 Long-term outcome of women who undergo panniculectomy at the time of gynecologic surgery. Gynecol Oncol 2006 0.79
76 Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer. Gynecol Oncol 2013 0.79
77 Sequential chemotherapy and irradiation in advanced stage endometrial cancer: A Gynecologic Oncology Group phase I trial of doxorubicin-cisplatin followed by whole abdomen irradiation. Gynecol Oncol 2009 0.77
78 Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer. Breast J 2010 0.77
79 Utility and cost-effectiveness of preoperative autologous blood donation in gynecologic and gynecologic oncology patients. Obstet Gynecol 2002 0.76
80 Cardiac arrest during laparotomy with argon beam coagulation of metastatic ovarian cancer. Int J Gynecol Cancer 2009 0.76
81 Relationship of ovarian neoplasms and body mass index. J Reprod Med 2005 0.76
82 The value of perioperative imaging in patients with uterine sarcomas. Gynecol Oncol 2009 0.75
83 Effect of a T0 radical hysterectomy specimen on survival for early stage cervical cancer. Gynecol Oncol 2007 0.75
84 Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer. Gynecol Oncol 2006 0.75
85 Double cervix with bilateral and synchronous HSIL associated with different high-risk HPV types. A case report. Acta Cytol 2004 0.75
86 Expression and localization of GRP75 in human epithelial tumors and normal tissues. Appl Immunohistochem Mol Morphol 2004 0.75
87 Primary peritoneal carcinoma presenting as adenocarcinoma on a Pap smear. A case report. J Reprod Med 2002 0.75
88 Acute abdominal pain with a calcified pelvic mass. J Pediatr Adolesc Gynecol 2003 0.75
89 Panniculectomy: improving lymph node yield in morbidly obese patients with endometrial neoplasms. Gynecol Oncol 2004 0.75